ImmunityBio bladder cancer therapy accepted for FDA review to expand label

ImmunityBio (NASDAQ:IBRX) said the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for review, aiming to expand the approved use of its immunotherapy drug Anktiva to treat a wider patient base with non-muscle invasive bladder cancer (NMIBC).